Conclusions and Recommendations Key messages for at-risk populations: The EVOKE trial failure does not invalidate GLP-1 agonists for preventionthe epidemiological signal remains strong, and these drugs may provide metabolic and cardiovascular benefits with potential cognitive co-benefits when used for approved indications SS-31s approval establishes precedent for mitochondrial-targeted therapeuticswatch this space for expanded indications Popular biohacker peptides (BPC-157, Dihexa, P21) have essentially no human cognitive evidence
AOD-9604 is a research peptide that has attracted significant scientific interest across the metabolic biology and adipose tissue research communities
Think of your brain as a dense, complex garden
Los medicamentos GLP-1 llegan al cerebro y causan una reduccin del apetito y, por lo tanto, de la ingesta de alimentos
Some researchers combine KPV with BPC-157 for comprehensive gut healing protocols
Polycystic ovary syndrome, or polycystic ovarian syndrome (PCOS), is a common womens health condition thats linked to obesity
